



PRESS RELEASE

17 January 2025 09:30:00 CET

AcouSort to meet with leading cell therapy and flow cytometry companies at two upcoming conferences

The Phacilitate Network consists of over 1,800 industry experts within cell and gene therapy. For 20 years, the network has hosted the Advanced Therapies Week for knowledge sharing, relationship building and deal making. January 20-23, AcouSort will attend Advanced Therapies Week in Dallas to interface with companies who are working on current and next generation technologies for cell and gene therapy – a space where AcouSort can play a key role.

AcouSort's participation in Phacilitate last year was highly successful, and the company has seen a growing interest in its solutions from the cell therapy community over the past twelve months. AcouSort currently has several ongoing collaborations and discussions which demonstrates that the technology has a vital role to play in making the manufacturing of cell therapies much more efficient. AcouSort has in advance scheduled meetings with relevant participating companies to make the most of this great opportunity.

“Advanced Therapies Week is the primary networking meeting for industry leaders within cell and gene therapy. It specifically focuses on next generation solutions supporting the biotech industry, thus making the event an excellent opportunity to present the fantastic benefits of our technology,” says Torsten Freltoft, AcouSort's CEO.

AcouSort will also participate in the CCMA, Canadian Cytometry and Microscopy Association conference in Ottawa on February 6-9, where Agnes Michanek, AcouSort's Commercial Director, will present the company's products and the capabilities of AcouSort's technology. The event is taking place at University of Ottawa, where AcouSort for the past year has been collaborating with Dr Vera Tang on the development of optimized applications for clean-up of dissociate tissue samples before flow cytometry analysis.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com



PRESS RELEASE

17 January 2025 09:30:00 CET

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).